Neophore appoints Michael Shih as Chief Executive Officer
NeoPhore appoints Michael Shih as Chief Executive Officer • Highly experienced corporate development leader with a track record of international pharma and biotech deal-making• New CEO to drive growth strategy to maximise the potential of drug discovery pipeline to treat cancer Press Release – London UK, 16 December 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the appointment of Michael Shih as … Continue reading Neophore appoints Michael Shih as Chief Executive Officer